Diabetologia. 2025 Mar 25. doi: 10.1007/s00125-025-06412-8. Online ahead of print.
ABSTRACT
AIMS/HYPOTHESIS: Diabetic retinopathy features damage to the retinal microvasculature that causes vessels to leak and proliferate and can lead to vision loss and blindness. Inflammation contributes to the development of diabetic retinopathy, but little is known about the role of the adaptive immune system, including the benefits of augmenting the Forkhead box protein P3 (Foxp3) regulatory T cell (Treg) compartment. We aimed to determine whether treatment with low-dose IL-2 expands and activates Tregs and reduces CD8+ T cells in the retina, and attenuates retinal inflammation and vasculopathy in murine models of diabetic retinopathy and neovascular retinopathy.
METHODS: Mouse models of streptozocin-induced diabetes and oxygen-induced retinopathy (OIR) were administered low-dose IL-2 (25,000 U) or vehicle (sterile water) by i.p. injection. Reporter mice expressing Foxp3 as a red fluorescent protein (RFP) conjugate or CD8 as a green fluorescent protein (GFP) conjugate were used to evaluate Foxp3+ Tregs and CD8+ T cells, respectively, in blood, lymphoid organs and retina using flow cytometry or confocal microscopy. Vasculopathy and the expression of angiogenic and inflammatory factors were assessed in the retina.
RESULTS: Low-dose IL-2 significantly expanded CD4+CD25+Foxp3+ Tregs in the blood and spleen of mouse models of OIR and diabetes (1.4- to 1.9-fold increase, p<0.01). This expansion enhanced Treg functionality, increasing the expression of cytotoxic T-lymphocyte-associated protein4 (CTLA4), programmed cell death protein1 (PD1) and T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT), and increased the ratio of Tregs to CD8+ T cells. This was accompanied in the retina by a twofold increase in Foxp3+ Tregs (diabetes: 3.01 ± 0.41 vs 5.90 ± 1.25 cells per field, p<0.001; OIR: 4.41 ± 1.48 vs 10.05 ± 2.91 cells per field, p<0.001) and a reduction in CD8+ T cells (diabetes: 4.65 ± 0.58 vs 3.00 ± 0.81 cells per field, p<0.01; OIR: 5.51 ± 1.33 vs 3.17 ± 1.14 cells per field, p<0.01). Low-dose IL-2 reduced the levels of the potent inflammatory factors intercellular adhesion protein1 and TNF and the chemokine IFNγ-inducible protein10 (IP-10) in the retina. Importantly, low-dose IL-2 treatment effectively attenuated retinal vasculopathy, with marked reductions in acellular capillaries (diabetes: 0.48-fold decrease, p<0.001), neovascularisation (OIR: 0.68-fold decrease, p<0.01) and vascular leakage, and expression of vascular endothelial growth factor.
CONCLUSIONS/INTERPRETATION: This study highlights the therapeutic potential of low-dose IL-2 to reduce retinal inflammation and severe vascular injury by boosting Tregs and reducing CD8+ T cells and inflammatory factors.
PMID:40133487 | DOI:10.1007/s00125-025-06412-8